Work

Development of Antiretroviral Resistance in Children With HIV in Low- and Middle-Income Countries

Year: 2013

Type: article

Abstract: With antiretroviral therapy (ART) recommended by the World Health Organization (WHO) for children aged <2 years with human immunodeficiency virus (HIV) and continuing global ART roll-out, ART coverage in children is rising. However ART coverage in children lags considerably behind that in adults (28% vs 58%). Long duration of therapy needed for HIV-infected children requires maximal efficacy, minimal toxicity, and prevention of development of drug resistance. This requires consideration of ways to improve sequencing of regimens during childhood to minimize development of resistance and treatment failure. We consider aspects of virological failure and development of resistance in vertically HIV-infected children in resource-limited settings. We review evidence guiding choices of first- and second-line ART, the impact of drugs given to prevent mother-to-child transmission, adherence issues and, availability of appropriate drug formulations. Recommendations made during the Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)/WHO meeting (October 2012) are summarized.

Source: The Journal of Infectious Diseases

DOI: 10.1093/infdis/jit115

Authors: F. Fitzgerald, M. Penazzato, D. Gibb

Institutions: North Middlesex University Hospital NHS Trust, North Middlesex Hospital, Medical Research Council

Language: English

Topic: HIV/AIDS drug development and treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Wellcome Trust, National Institute for Health and Care Research, Medical Research Council